Park EM, Wang M, Bowers SM, Muriel AC, Rauch PK, Edwards T, Yi SM, Daniel B, Hanson LC, Song M-K. Adaptation and psychometric evaluation of the parenting concerns questionnaire-advanced disease. Am J Hosp Palliat Care. 2021 Oct 7. doi: 10.1177/10499091211049801
Haque R, Shi JM, Telford C, Avila C, Alvarado M, Tiller GE, Dalvi T, Gutierrez L, Tyczynski J, Kaye JA. Survival outcomes in BRCA1 or BRCA2 mutation carriers and the influence of triple-negative breast cancer subtype. Perm J. 2018 Oct 11;22:17-197. doi: 10.7812/TPP/17-197
Wilson M, Lucas A, Cameron A, Luo M. Budget impact of adding vedolizumab to a health plan formulary as a first-line biologic option for ulcerative colitis and crohn's disease. Am Health Drug Benefits. 2018 Jul;11(5):253-62.
Gold R, Esterberg E, Hollombe C, Arkind J, Vakarcs PA, Tran H, Burdick T, Devoe JE, Horberg MA. Low back imaging when not indicated: a descriptive cross-system analysis. Perm J. 2016;20(2):25-33. doi: 10.7812/TPP/15-08
Schmidt MA, Naleway AL, Esterberg EJ, DeBess EE, Biggs C, Hall AJ. Rapid, active surveillance for medically-attended acute gastroenteritis and norovirus infection in a managed care environment. Poster presented at the Annual HMO Research Network Conference Spring 2015; March 2015. Long Beach, CA. [abstract] J Patient Cent Res Rev. 2015 Apr 30; 2:140-1. doi: 10.17294/2330-0698.1195
Harris JB, Ward MA, Schwab P. Is response-guided therapy being applied in the clinical setting? The hepatitis C example. Am Health Drug Benefits. 2015 Feb;8(1):22-8.
Sacco P, Capkun-Niggli G, Zhang X, Jose R. The economic burden of fragile x syndrome: healthcare resource utilization in the United States. Am Health Drug Benefits. 2013 Mar;6(2):73-83.
Lennert B, Bibeau W, Farrelly E, Sacco P, Schoor T. Assessment of treatment patterns and patient outcomes in levodopa-induced dyskinesias (ASTROID): a US chart review study. Am Health Drug Benefits. 2012 Sep;5(6):347-58.